Correction: A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells

In this article (Cancer Res 2013;73:5169–82), which was published in the August 15, 2013, issue of Cancer Research (1), the "Cytotoxic compounds" section on page 5170 was missing a reference and should read as follows:

The anti-tropomyosin compound TR100 was designed and synthesized by T.A. Hill and A. McCluskey (23). Cytochalasin D was purchased from Sigma-Aldrich. Compounds were solubilized in DMSO to give stock concentrations of 50 mmol/L (TR100) and 4 mmol/L (cytochalasin D).

The new reference #23 is as follows:


The references in the article have been renumbered accordingly. The authors regret this error. The online version of the article has been corrected and no longer matches the print.

Reference


Published OnlineFirst August 29, 2013.
doi: 10.1158/0008-5472.CAN-13-2395
©2013 American Association for Cancer Research.
Correction: A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells


Updated version  Access the most recent version of this article at: doi:10.1158/0008-5472.CAN-13-2395

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.